Article
TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Apr 2012
Gaidzik Verena I, Paschka Peter, Späth Daniela, Habdank Marianne, Köhne Claus-Henning, Germing Ulrich, von Lilienfeld-Toal Marie, Held Gerhard, Horst Heinz-August, Haase Detlef, Bentz Martin, Götze Katharina, Döhner Hartmut, Schlenk Richard F, Bullinger Lars, Döhner Konstanze
Abstract excerpt
PURPOSE: The tet oncogene family member 2 (TET2) gene was recently identified to be mutated in myeloid disorders including acute myeloid leukemia (AML). To date, there is increasing evidence for a functional role of TET2 mutations (TET2(mut)) in AML. Thus, we explored the frequency, gene-expression pattern, and clinical impact of TET2(mut) in a large cohort of patients with AML in the context of other...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
